Form 4 for IDXX Idexx Laboratories
Accepted 2025-11-10 00:00:00 ET · period of report 2025-11-07 · accession 0000874716-25-000168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-10 | 2025-11-07 | IDXX | Hunt Nimrata | EVP | S - Sale+OE | $703.34 | -9,425 | 25.5K | -27% | -$6.63M |
| DM | 2025-11-10 | 2025-11-07 | IDXX | Hunt Nimrata | EVP | M - OptEx | $382.28 | +12.5K | 30.6K | +69% | +$4.79M |
| DM | 2025-11-10 | 2025-11-07 | IDXX | Hunt Nimrata | EVP | M - OptEx | $0.00 | -12.5K | 1,604 | -89% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-07 | S | D | 1,465 | $703.73 | 23,994.94 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2025-11-07 | S | D | 1,468 | $704.87 | 22,526.94 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 3 | Common | Common Stock | 2025-11-07 | S | D | 1,378 | $705.54 | 21,148.94 | D | — | — | (F5) Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Common | Common Stock | 2025-11-07 | M | A | 7,125 | $288.78 | 25,168.94 | D | — | — | (F1) Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025. |
| 5 | Common | Common Stock | 2025-11-07 | M | A | 5,405 | $505.53 | 30,573.94 | D | — | — | |
| 6 | Common | Common Stock | 2025-11-07 | S | D | 5,114 | $702.20 | 25,459.94 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 7 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2025-11-07 | M | D | 7,125 | $0.00 | 0 | D | $288.78 · — to 2030-02-13 | 7,125 Common Stock | (F6) Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021. |
| 8 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2025-11-07 | M | D | 5,405 | $0.00 | 1,604 | D | $505.53 · — to 2032-02-13 | 5,405 Common Stock | (F7) Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. |